Replies to post #516545 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Yes. The P3 trial succeeded for both nGBM and rGBM. The helmet will lose quite a bit of business.

[biosectinvestor]

The updated SAP, while still blinded, addressed this issue. Plus this is a rare and orphan disease. Recurrent patients to treat are even less AND there is no standard of care for rGBM. So this would be an improvement over no treatment AND if it is approved for newly diagnosed, then extending the indication to recurrent patients based on that data will, as I have explained previously given the 21st Century Cures Act, be very easy, especially with that data.